Publication | Closed Access

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

ImmunologyClinical TrialsClinical DermatologyPlacebo-controlled TrialDermatologyPhoenix 2ImmunotherapyMedicineExperimental Dermatology52-Week Results